Psoriasis treatment using minimally manipulated umbilical cord-derived mesenchymal stem cells: A case report

Abstract

BACKGROUND Psoriasis is a chronic autoimmune disease that usually manifests as a red scaly epidermis, induration, and hyperproliferation of basal keratinocytes. About 2% of the world’s population suffers from psoriasis but there are no clear therapeutics yet. Recently, mesenchymal stem cells (MSCs) have been regarded as a therapeutic alternative for autoimmune diseases, as they possess immunosuppressive effects without risks. Human umbilical cord-derived MSCs effectively regulate immune cells and are characterized by low immunogenicity, which has many advantages in treating immune diseases. CASE SUMMARY The patient was a 47-year-old male, diagnosed with psoriasis in 1995. He had received various treatments for 25 years, but the psoriatic condition was not significantly improved. He was given three rounds of minimally manipulated umbilical cord-derived MSCs over 2 wk. The erythema gradually disappeared. Three months after the 1 st round, all erythema completely disappeared, and the psoriasis did not recur. CONCLUSION Minimally manipulated umbilical cord-derived MSC transplantation can potentially treat patients who suffer from psoriasis.

Therapeutic potential of mesenchymal stem cells for refractory inflammatory and immune skin diseases

“…A male patient who had received various psoriasis treatments for 25 years without ideal efficacy showed significant improvement after intravenous transplantation (3.0 × 10 6 cells/mL) and local transplantation (1.0 × 10 6 cells/mL) of umbilical cord-derived MSCs transplantation. 49 And in the long follow-up of 4 to 5 years, a female patient showed no psoriatic relapse signs after three infusions and two more consolidating infusions of umbilical cord-derived MSCs (1.0 × 10 6 /kg for each time). Unexpected psoriasis relief was observed in a male patient who had suffered psoriasis for 12 years during the treatment of newly diagnosed diffuse large B-cell lymphoma (stage IV) with standard lymphoma chemotherapies and autologous hematopoietic stem cell transplantations.…”

Indirubin combined with umbilical cord mesenchymal stem cells to relieve psoriasis-like skin lesions in BALB/c mice

“…They also have low immunogenicity and have many advantages in the treatment of immune-related diseases. Reports have indicated that hUC-MSCs transplantation can treat psoriasis patients ( 4 ). hUC-MSCs are a safer psoriasis treatment option than topical glucocorticoids and can effectively avoid the adverse reactions caused by topical glucocorticoids on the epidermis.…”

“…The effects of epidermal stem cells and stem cells on T cells have been found. The dysfunction of various types of stem cells may be the main reason for the dysregulation of inflammatory response in psoriasis ( 3 , 4 ). Human umbilical cord mesenchymal stem cells (hUC-MSCs) are characterized by low immunogenicity, high expansion rate in vitro , and pluripotent differentiation potential, and they can be used as the ideal choice of mesenchymal stem cells for the treatment of psoriasis.…”

Therapeutic effects of mesenchymal stem cells and their derivatives in common skin inflammatory diseases: Atopic dermatitis and psoriasis

“…After both intravenous and local administration of UC-MSCs, his erythema gradually disappeared (10 ml for intravenous administration with 3 × 10 6 cells/ml in 0.9% physiological saline and 2–4 ml for local administration with 1 × 10 6 cells/ml in 0.9% physiological saline). The follow-up was 122 days, and the symptom was gradually becoming better without any side effects ( 77 ). In addition, in a 17-patient clinical trial, Cheng et al.…”